| Document |
Document Title |
|
WO/2014/003405A1 |
The present invention relates to a novel compound, and a light emitting device comprising the same. The compound of the present invention has excellent electron transport characteristics, and thus can be used as a luminous material for a...
|
|
WO/2013/185871A1 |
The present invention relates to organic electroluminescent devices comprising compounds of the formula (1), in particular as blue singlet emitting materials in an electroluminescent layer.
|
|
WO/2013/182071A1 |
Provided is a process for producing a hydrocyanic acid derivate by the comprehensive utilization of coke oven gas, comprising separating methane gas, hydrogen gas and carbon monoxide gas with a relatively low quality requirement by means...
|
|
WO/2013/178575A1 |
The present invention relates to compounds of general formula I, (I) wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate ...
|
|
WO/2013/176421A1 |
The present invention relates to: a method for preparing a tricyanoalkoxyalkane compound, and more specifically, to a nonaqueous electrolyte solution for a lithium secondary battery, comprising a tricyanoalkoxyalkane compound prepared by...
|
|
WO/2013/176088A1 |
The present invention provides a method for producing a nitrile represented by general formula (1) (in the formula, R denotes an optionally substituted alkyl group, alkenyl group, dienyl group, aralkyl group or aryl group having a total ...
|
|
WO/2013/175053A1 |
Compounds of formula (I), wherein R1 is as defined in the claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.
|
|
WO/2013/168023A1 |
Provided are compounds, pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical,...
|
|
WO/2013/160670A1 |
The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc1 complex. The invention extends to the use of such inhibitors in agrochemicals and in pharmaceuticals, for treating microbi...
|
|
WO/2013/160229A1 |
The present invention relates to an improved process for batchwise or continuous isomerization of cis-2-pentenenitrile to 3-pentenenitriles in the presence of 1,4-diazabicyclo[2.2.2]octane as a catalyst.
|
|
WO/2013/161980A1 |
The purpose of the present invention is to provide: a compound having an sEH-inhibiting activity; and a medicinal agent which has an sEH-inhibiting activity and therefore can exhibit a therapeutic effect and a prophylactic effect on chro...
|
|
WO/2013/156341A1 |
The present invention relates to novel bifunctional branched and unsaturated compounds of formula (I), obtained from fatty acids. The invention also relates to a method for preparing same and to the uses thereof, in particular as monomer...
|
|
WO/2013/149566A1 |
Provided herein are processes for preparing a compound of Formula (V), comprising nitrating a compound of Formula (IV), with a nitrating agent in the presence of a catalyst.
|
|
WO/2013/149364A1 |
Disclosed in the present invention is a method for synthesizing 1-hydroxymethyl cyclopropyl acetonitrile, comprising firstly using a compound of tribromo-neopentyl alcohol 1 as a starting raw material and acetylating tribromo-neopentyl a...
|
|
WO/2013/152170A1 |
Compounds having therapeutic potential as androgen receptor modulators, and methods of making such compounds, are provided. The compounds are structurally related to bicalutamide but bear at least one difluoromethyl or C2 to C5 perfluoro...
|
|
WO/2013/144500A1 |
The invention relates to a method for synthesizing ivabradine of formula (I) and its addition salts with a pharmaceutically acceptable acid.
|
|
WO/2013/143333A1 |
A complex, an alignment material, an alignment film, a preparation method of the alignment film, and an application of the alignment material. The general formula of the complex is A-B-C-B'-D, where A represents a photoreactive end group...
|
|
WO/2013/145666A1 |
An organic electroluminescent element which comprises: a positive electrode; a negative electrode; two or more light emitting units that are held between the positive electrode and the negative electrode and respectively have a light emi...
|
|
WO/2013/146609A1 |
A method for purifying acetonitrile, said method comprising steps for adding an alkali to water-containing acetonitrile that has been produced by an ammoxidation reaction, reacting the alkali therewith, supplying the resulting reaction m...
|
|
WO/2013/145667A1 |
Provided is an organic electroluminescence element having, in this order, an anode, at least one organic thin-film layer having a light emitting layer, a donor containing layer, an acceptor containing layer, and a cathode with light tran...
|
|
WO/2013/138863A1 |
The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer.
|
|
WO/2013/136073A1 |
The present invention relates to derivatives of compounds which are known to be of use in the field of agriculture. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active c...
|
|
WO/2013/132006A1 |
The present invention describes a method for synthesising 2-aminobiphenyls and derivatives thereof. This method can be performed cost-effectively and is based on selective reactions. Functionalised biphenyl compounds are of great interes...
|
|
WO/2013/129385A1 |
The present invention relates to a method for producing acrylonitrile, the method comprising a gas-phase catalytic ammoxidation step for obtaining acrylonitrile by bringing a starting gas comprising propylene, molecular oxygen, and ammon...
|
|
WO/2013/128425A1 |
The subject matter of the present invention is compounds of formula (I), processes for preparing same, and also uses thereof in the therapeutic field and in the materials field.
|
|
WO/2013/129424A1 |
The present invention pertains to a method that is for producing acrylonitrile and that is characterized by containing a gas-phase contact ammoxidation step for performing gas-phase contact ammoxidation by causing a starting material gas...
|
|
WO/2013/129363A1 |
This method for producing acrylonitrile is characterized by including a gas-phase contact ammoxidation step for causing a starting material gas containing propylene, molecular oxygen, and ammonia to contact a fluidized bed catalyst to ca...
|
|
WO/2013/130436A1 |
The present invention relates to processes for preparing 3-methylsulfonylpropionitrile. The processes provide a good yield and a good purity of the final product and provide a controllable reaction. The present invention also relates to ...
|
|
WO/2013/125639A1 |
The purpose of the present invention is to effectively reduce deposits of molybdenum oxides on a contact surface with which a molybdenum compound freed from a metal oxide catalyst makes contact in a gas phase reaction device for carrying...
|
|
WO/2013/124280A1 |
The present invention relates to the field of organic synthesis and describes the synthesis of specific intermediates suitable for the preparation of triazolopyrimidine compounds such as ticagrelor.
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/121151A1 |
The present invention relates to a process for producing dinitrile, characterized in that it comprises at least one step of reaction between a sodium disalt of a diacid and an ammonia source, under the following conditions: - the ammonia...
|
|
WO/2013/120808A1 |
The present invention is directed to a process for the manufacture of methyl limonitrile comprising a mixture of 3,7-dimethyl-2,6-nonadiene nitrile, 3,7-dimethyl-3,6-nonadiene nitrile and 7-methyl-3-methylene-6-nonene nitrile comprising ...
|
|
WO/2013/120805A1 |
The present invention is directed to a process for the manufacture of methyl limonitrile comprising a mixture of 3,7-dimethyl-2,6-nonadiene nitrile, 3,7-dimethyl-3,6-nonadiene nitrile and 7-methyl-3-methylene-6-nonene nitrile comprising ...
|
|
WO/2013/117601A1 |
The invention relates to a method for producing substituted anthranilic acid derivatives of formula (I), in which R1, R2, R3, and R4 have the meanings specified in the description, by reacting the compounds of general formula (IV) in the...
|
|
WO/2013/118751A1 |
An amide compound can be produced efficiently by reacting a carboxylic acid ester compound and a primary or secondary monoamine compound in the presence of a catalyst obtained by bonding at least one alkoxy group to a metal or semimetal ...
|
|
WO/2013/115040A1 |
Disclosed is a secondary battery, which is provided with an electrolyte solution and a negative electrode that contains a negative electrode active material, and wherein the negative electrode active material contains silicon and the ele...
|
|
WO/2013/113037A1 |
New and improved processes for the production of 1, 1 -disubstituted ethylenes.
|
|
WO/2013/113035A1 |
An improved process for the production of meihylidene malonates is attained by use of select sminium salt reactanis.
|
|
WO/2013/109972A2 |
The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), interm...
|
|
WO/2013/104829A1 |
The invention relates to novel arylamide derivatives having formula (I), and stereoisomers and pharmaceutically acceptable salts thereof, where RA, RB, RC, R', R'', z and X are as defined in the claims. The arylamide derivatives of formu...
|
|
WO/2013/098416A2 |
The present invention relates to the use of compounds for the treatment or prevention of pain in mammals, in particularly in human beings, and also to a process for preparing these compounds.
|
|
WO/2013/097773A1 |
The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.
|
|
WO/2013/084237A1 |
This invention relates to deuterated tetramethyl dioic acids, compositions comprising them and uses thereof in the treatment of Metabolic Syndrome and any diseases, disorders or symptoms associated therewith.
|
|
WO/2013/079888A1 |
The present invention relates to a method for synthesising a ω-amino acid compound having formula HOOC-R'-CH2NH2, where R is an alkyl radical comprising between 6 and 15 carbon atoms or an alkylene radical comprising between 6 and 15 ca...
|
|
WO/2013/079849A1 |
The invention relates to a method for cleaving unsaturated fatty chains. Said method includes an oxidative cleavage step, wherein at least one fatty acid derivative, comprising at least one unsaturation with hydrogen peroxide in the pres...
|
|
WO/2013/077543A1 |
The present invention relates to a method for preparing phthalonitriles by the ammoxidation of xylenes. Reaction raw materials are separately supplied from a fixed layer reactor to two or more branches of the reactor, and thus, the tempe...
|
|
WO/2013/072466A1 |
The present invention concerns the production of compounds comprising nitrile functions and cyclic imide compounds. More specifically, the invention relates to the production of compounds comprising nitrile functions from compounds compr...
|
|
WO/2013/065189A1 |
The present invention provides a method for producing a reduction reaction product, wherein recovery of the reaction solvent and/or distillation is carried out after adding a nitrogen-containing compound into a reaction liquid of a reduc...
|
|
WO/2013/062028A1 |
Provided are a novel compound having an antiviral effect, particularly HIV replication-inhibiting activity, and a medical drug, particularly an anti-HIV drug, containing the same. The compound is represented by Formula (I) (where the bro...
|
